ALISO VIEJO, Calif., Feb. 23, 2017 /PRNewswire/ -- Calhoun Vision, Inc., the global leader of adjustable intraocular
Despite many improvements in modern-day cataract surgery technology, post-operative results rarely achieve the visual goals expressed by the patient. Residual refractive error, even after premium cataract surgery, is still common due to unpredictable wound healing as well as variations in post-operative lens position. RxSight's Light Adjustable Lens (RxLAL™) addresses this by enabling physicians to make office-based refractive adjustments to the lens after the cataract is removed and the eye is stable. Importantly, the patient is also actively engaged in the process to realize their lifestyle vision expectations.
RxSight also announced the filing of its initial PMA with the U.S. Food and Drug Administration (FDA) as well as the addition of veteran health care executive and entrepreneur William Link, PhD to its Board of Directors.
About RxSightRxSight is the global leader in adjustable intraocular lens technology. Using a proprietary light treatment that produces precise modifications in lens curvature, RxSight's Light Adjustable Lens (RxLAL™) enables doctors and patients to predictably optimize vision after cataract surgery through an office based IOL enhancement. Additional information about RxSight can be found at www.rxsight.com.
Caution: In the United States, RxSight's Light Adjustable Lens is an investigational device and is limited by Federal (United States) law to investigational use.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/calhoun-vision-becomes-rxsight-300412152.html
Subscribe to our Free Newsletters!
Erythropoietin is a hormone secreted by kidneys in response to low oxygen levels in tissues ...
Local anesthesia is a type of anesthesia generally used to block pain sensation only in a specific ...
Sea food allergy is the adverse response of the body''s immune system to the proteins present in ...View All